WAT enters its May 21 earnings report carried by a wave of analyst upgrades — but a sharp pullback in the past week signals investors are not yet convinced.
The analyst story is the clearest setup heading into the print. After Q1 results on May 5 delivered a +15.8% single-day surge and a 16.7% five-day gain, the Street moved quickly to lift targets. Wells Fargo raised to $370, Barclays lifted to $425, UBS moved to $375, and JP Morgan pushed to $345 — all within days of that beat. Despite that cluster of upward revisions, the consensus remains a firm "Hold" with a mean target near $398, roughly 21% above the current $329 price. That gap suggests the Street sees value but is not ready to chase the stock after its post-Q1 pop.
The tension is that the stock has already given back much of that gain. After spiking above $370 post-earnings, WAT has shed 7.3% over the past week to $329.22 — a reversal that frames Thursday's Q2 report as a retest of whether that initial enthusiasm was justified. Options positioning reinforces the more balanced read: the put/call ratio at 0.83 is actually below its 20-day average of 0.89, suggesting options traders are not aggressively buying downside protection. That is a mild tilt toward calls, not the defensive crouch you often see ahead of uncertain prints.
Short interest adds further context without dominating the story. At 5.7% of the free float, WAT carries a meaningful — though not extreme — short position. Notably, that figure has eased about 6.5% over the past week after building by roughly 9% over the prior month, consistent with shorts trimming after the post-Q1 beat rather than pressing a new thesis. Borrow availability remains loose: cost to borrow has dropped 35% over the week to just 0.31%, and the borrow market shows no squeeze pressure heading in.
The bull case rests on forward earnings momentum — the stock ranks in the 84th percentile on 12-month forward EPS estimate growth, and the analyst recommendation differential sits in the 91st percentile, meaning the directional drift of ratings is unusually constructive relative to peers. Bears point to valuation compression: the EV/EBITDA multiple has contracted 0.7 turns over 30 days and P/B has slipped 0.6x, suggesting the re-rating from Q1 has partially unwound. Peers confirm the sector is under pressure, with RVTY, CRL, and RGEN each down 6–17% on the week — a reminder that the broader life-sciences tools group is navigating a challenging funding environment.
Thursday's print tests whether Waters can validate the target upgrades with Q2 guidance strong enough to hold the stock above the levels that triggered them.
See the live data behind this article on ORTEX.
Open WAT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
